Eli Lilly (United Kingdom)

Eli Lilly UK is the British subsidiary of the global pharmaceutical company Eli Lilly and Company, developing breakthrough treatments in diabetes, obesity, oncology, immunology, and neuroscience. Key products include Mounjaro (tirzepatide) for type 2 diabetes and chronic weight management, Trulicity (dulaglutide) for type 2 diabetes, Verzenio (abemaciclib) for hormone receptor-positive breast cancer, Taltz (ixekizumab) for psoriasis and psoriatic arthritis, and Emgality (galcanezumab) for migraine prevention.